View Older Stories

Apr 7, 2026 04:31PM Unicycive Therapeutics (UNCY) PT Lowered to $23 at Brookline Capital Markets

Apr 6, 2026 08:38AM Unicycive Therapeutics (UNCY) PT Lowered to $15 at Benchmark

Apr 2, 2026 06:43AM Unicycive Therapeutics (UNCY) PT Lowered to $40 at Guggenheim

Apr 1, 2026 06:59AM H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)

Feb 17, 2026 09:15AM Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Jan 29, 2026 07:05AM FDA accepts Unicycive drug application resubmission with June review date

Dec 30, 2025 06:36AM Guggenheim Reiterates Buy Rating on Unicycive Therapeutics (UNCY)

Dec 29, 2025 07:05AM Unicycive resubmits drug application for kidney disease treatment

Dec 8, 2025 07:32AM Piper Sandler on Biotechnology: 'What Commercial Names to Own in 2026?'

Dec 1, 2025 01:41PM Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Nov 12, 2025 08:36AM Unicycive Therapeutics (UNCY) PT Lowered to $63 at Lucid Capital Markets

Nov 12, 2025 08:10AM Unicycive Therapeutics, Inc (UNCY) Misses Q3 EPS by 46c

Nov 3, 2025 09:10AM Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Investigates Claims on Your Behalf

Oct 29, 2025 06:49AM Unicycive Therapeutics (UNCY) PT Raised to $22 at H.C. Wainwright

Oct 28, 2025 07:06AM Unicycive expects to resubmit drug application by year-end after FDA meeting

Oct 15, 2025 08:59AM Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Investigates Claims on Your Behalf

Sep 15, 2025 08:57AM Unicycive Therapeutics (UNCY) PT Raised to $21 at Benchmark to Reflect Reverse Split

Aug 18, 2025 07:05AM Unicycive receives patent for kidney disease drug UNI-494

Aug 14, 2025 04:11PM Unicycive Therapeutics, Inc. (UNCY) Misses Q2 EPS by 143c

Jul 24, 2025 08:02AM Unicycive publishes pivotal trial data for kidney disease drug

Jul 8, 2025 08:31AM Unicycive Therapeutics (UNCY) regains NASDAQ compliance after reverse split

Jul 1, 2025 09:34AM Unicycive (UNCY) Will Seek Type A Meeting to Resolve CRL Issues: Benchmark

Jun 30, 2025 07:05AM Unicycive Therapeutics (UNCY) Announces Receipt of CRL for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Jun 30, 2025 07:01AM Unicycive Therapeutics, Inc (UNCY) Halted, News Pending

Jun 17, 2025 07:01AM Unicycive Therapeutics, Inc (UNCY) Announces 1:10 Reverse Share Split

Jun 11, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)

Jun 10, 2025 06:02AM Unicycive Therapeutics (UNCY) Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat

Jun 4, 2025 06:19AM Lucid Capital Markets Starts Unicycive Therapeutics (UNCY) at Buy

May 21, 2025 08:48AM Benchmark Reiterates Speculative Buy Rating on Unicycive Therapeutics (UNCY)

May 14, 2025 04:59PM Unicycive Therapeutics, Inc. (UNCY) Misses Q1 EPS by 51c

Apr 11, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)

Apr 10, 2025 09:14AM Benchmark Reiterates Speculative Buy Rating on Unicycive Therapeutics (UNCY)

Apr 1, 2025 06:46AM Unicycive Therapeutics (UNCY) PT Raised to $7.50 at H.C. Wainwright

Feb 20, 2025 07:02AM Unicycive Therapeutics, Inc (UNCY) Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor

Jan 28, 2025 07:02AM Unicycive Therapeutics (UNCY) Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

Jan 7, 2025 07:01AM Unicycive Therapeutics (UNCY) Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

Nov 13, 2024 05:05PM Unicycive Therapeutics, Inc. (UNCY) Tops Q3 EPS by 10c

Nov 12, 2024 07:52AM H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)

Nov 11, 2024 07:01AM Unicycive Therapeutics (UNCY) Announces U.S. FDA Acceptance of the NDA for Oxylanthanum Carbonate

Oct 14, 2024 07:04AM Unicycive Therapeutics, Inc (UNCY) Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology

Oct 10, 2024 06:58AM H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)

Oct 9, 2024 07:04AM Unicycive Therapeutics (UNCY) Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

Sep 7, 2024 08:00PM Here's the list of biotech stocks that have key data catalysts in 2025

Sep 6, 2024 06:52AM Benchmark Reiterates Speculative Buy Rating on Unicycive Therapeutics (UNCY)

Sep 4, 2024 07:27AM H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)

Sep 3, 2024 07:03AM Unicycive Therapeutics (UNCY) Announces Submission of NDA to U.S. FDA for Oxylanthanum Carbonate for Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Aug 16, 2024 06:44AM Unicycive Therapeutics (UNCY) PT Lowered to $2.50 at H.C. Wainwright

Aug 14, 2024 04:02PM Unicycive Therapeutics, Inc. (UNCY) Misses Q2 EPS by 9c

Jul 17, 2024 07:03AM Unicycive Therapeutics, Inc (UNCY) Receives US Patent for UNI-494 to Treat Acute Kidney Injury

Jul 11, 2024 10:32AM H.C. Wainwright Reiterates Buy Rating on Unicycive Therapeutics (UNCY)

View Older Stories